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We report a novel germline Met53Val mutation in CDKN2A from a large melanoma-prone family; this mutation
occurs in exon 2 of CDKN2A where p16 and alternative reading frame (ARF) both share transcript sequences. The
previously reported Met53Ile and the current Met53Val mutations are coupled to distinct Asp68His and Asp67Gly
alterations in ARF, respectively. The coincidence of second, independent p16 Met53 alteration that differentially
alters ARF suggests that there may be selectivity for targeting the p16 transcript over the ARF transcript.
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Germline mutations in the CDKN2A gene have now been
identified in many hereditary melanoma kindreds worldwide
(Kefford et al, 1999; Bishop et al, 2002). The gene is com-
prised of four coding regions—exons 1a, 1b, 2, and 3. The
transcript derived from exons 1a, 2, and 3 yields the neg-
ative cell cycle regulator, p16, whereas the transcript
spliced from exons 1b, 2, and 3 generates ARF, an inhib-
itor of the p53-destabilizing protein, MDM2 (Ruas and
Peters, 1998; Stott et al, 1998). Since p16 and ARF both
share exon 2, mutations in this region of CDKN2A often
affect both proteins. In this regard, mutagenesis of CDKN2A
is extremely efficient for tumorigenesis—a single genetic
lesion can impair two critical brakes on oncogenesis, the
retinoblastoma (RB) and p53 effector arms.
The p16 protein is composed of four tandem ankyrin re-
peats. Sequence analysis reveals that exon 2 encodes for
three of four ankyrin repeats whereas crystallographic and
biochemical studies have demonstrated an essential role for
these ankyrin modules in binding of p16 to its cognate partner,
CDK4 (Brotherton et al, 1998; Ruas and Peters, 1998; Ruas
et al, 1999). A recurrent germline mutation in the second an-
kyrin repeat, Met53Ile, has been reported worldwide and is
believed to be a founder mutation (Pollock et al, 1998; Bishop
et al, 2002); yeast two-hybrid analysis have shown functional
abrogation of p16 due this codon 53 substitution (Monzon
et al, 1998). Since the Met53Ile mutation in p16 occurs in the
shared second CDKN2A exon, the ARF sequence also har-
bors an Asp68His alteration. On structure alone, the Met53Ile
change is more conservative than the charge reversion at-
tendant to the Asp68His alteration. Thus, it is impossible to
determine if the driving force behind the melanoma tumor
promotion is more closely aligned with the p16 or the ARF
disruption. We report a novel germline Met53Val alteration in
p16 that affects ARF at Asp67 rather than the Asp68, which
accompanies Met53Ile. The presence of this second inde-
pendent p16 mutation at codon 53, which also leads to a
melanoma-prone phenotype, suggests that the target for exon
2 mutagenesis is p16 of Met53 rather than ARF of Asp68.
The patient’s family is shown in Fig 1A. At age 25, the
patient developed three thin primary superficial spreading
melanomas. She grew up on the Atlantic coast and reports
significant sun exposure in her youth. Her mother, maternal
uncle, maternal grandfather and a maternal once-removed
first cousin all had melanoma; her uncle died from the dis-
ease at age 29. Self-reported history suggests melanoma
occurring in six generations although medical record doc-
umentation is available only for three generations.
Through an IRB-approved protocol (Massachusetts Gen-
eral Hospital and Dana Farber Cancer Center), we collected
blood from our patient, her affected mother, her unaffected
sister, her unaffected brother and an unaffected once-
removed first cousin who has an affected sister. Patients
gave their written informed consent. We performed direct
sequencing of CDKN2A exons 1a and 2 using primers and
conditions that have been previously published (Hogg et al,
2001). As shown in Fig 1B, the patient harbors a 157G4A
transition, which translates to Met53Val and Asp67Gly sub-
stitutions in p16 and ARF, respectively. By comparison, the
canonical Met53Ile mutation results from a 159G4C trans-
version. Evaluation of the family members for whom we
have DNA samples showed that both living affecteds in the
family (patient and mother) are carriers of the mutation
whereas two of three living non-affecteds are non-carriers.
The patient’s brother also harbors the mutation but has not
developed melanoma to date. It is possible that this indi-
vidual has not yet exhibited melanoma due to his relatively
young age (i.e., 40).
We report a second, distinct, mutation at Met53 of p16.
Although we have limited familial samples, the mutation
does appear to segregate in most cases. Since there are no
other kindreds reported with this alteration, it is impossible
to determine if this change is unique or if other undetected
Met53Val families exist. The compilation of germline p16
mutations in hereditary melanoma suggests that many mu-
tations affect the second and third ankyrin repeats of
p16(Ruas and Peters, 1998; Piepkorn, 2000). Furthermore,
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biochemical and structural data support critical contact
points between the exon 2 domain of p16 and CDK4 (Koh
et al, 1995; Brotherton et al, 1998). Thus, the contribution of
the CDKN2A exon 2 domain to p16 functionality is fairly
well-established.
The rarity of ARF-specific exon 1bmutations compared to
the p16-specific exon 1a alterations argues for p16 inacti-
vation as the rate-limiting step in melanoma susceptibility.
Since CDKN2A exon 2 is shared by both ARF and p16,
however, it has been difficult to tease apart their distinct
contributions. Clark et al (2002) found that the amino-termi-
nal half of ARF, encoded by exon 1b, appears sufficient to
bind MDM2 and impede MDM2-mediated degradation of
p53 degradation thereby raising questions regarding the es-
sential functions of the exon 2 domain of ARF. To this end,
our finding of another, independent, germline Met53 muta-
tion that differentially affects ARF suggests that Met53 of p16
is the critical genetic target for the aspiring cancer cell. Our
results do not, however, eliminate the possibility that both
Asp67 and Asp68 are critically important in ARF function;
clearly, structure–function analyses of ARF are still needed.
In conclusion, the segregation with disease and codon
specificity suggests that the novel germline Met53Val
change is melanoma predisposing; extant biochemical
and structural data also support a functional consequence
for this alteration. This mutation offers a unique view of p16/
ARF inputs into melanoma tumorigenesis as distinct muta-
tional events at a single same amino acid (ie. Met53) do not
occur frequently with CDKN2A.
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Figure 1
Met53Val Pedigree and Mutation. (A). The patient’s pedigree. The
proband is indicated by the arrowhead. Abbreviations for cancers in-
clude MEL, melanoma; BR, breast; LY, lymphoma. Melanomas are
shaded black on the right upper quadrant; other cancers are shaded
gray in various quadrants. Mutation status: (þ ) carriers, () non-
carriers. (B). The G/A transition at nt167 (starting from the first ATG of
the p16 transcript) is indicated by the blue arrow.
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